Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SCYNEXIS ( (SCYX) ) has shared an update.
On May 19, 2026, SCYNEXIS stockholders approved an amendment to the company’s certificate of incorporation authorizing a reverse stock split in a range between 1-for-5 and 1-for-10 and a reduction in authorized shares, with 44,826,378 votes for, 6,708,960 against and 102,965 abstaining. Following this approval, the board selected a one-for-eight ratio and authorized a Certificate of Amendment to implement the split and reduce authorized common shares from 150,000,000 to 18,750,000, effective May 29, 2026.
Under the one-for-eight reverse stock split, every eight issued and outstanding shares of common stock will automatically convert into one share, with no change to the $0.001 par value and no issuance of fractional shares, which will instead be settled in cash. The reverse split will proportionately affect all shareholders and outstanding equity awards, reducing share counts and increasing exercise prices without materially changing ownership percentages, and the stock is scheduled to begin trading on a split-adjusted basis on Nasdaq on June 1, 2026 under the existing SCYX ticker with a new CUSIP 811292 309.
The most recent analyst rating on (SCYX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on SCYNEXIS stock, see the SCYX Stock Forecast page.
Spark’s Take on SCYX Stock
According to Spark, TipRanks’ AI Analyst, SCYX is a Neutral.
The score is held back primarily by weak financial performance (recent large losses and ongoing cash burn) and bearish technicals (downtrend with negative momentum). Offsetting these risks, recent corporate actions—SCY-770 acquisition and the $40M financing extending runway to mid-2029—meaningfully improve strategic positioning and liquidity, but not enough to outweigh current operating weakness.
To see Spark’s full report on SCYX stock, click here.
More about SCYNEXIS
SCYNEXIS, Inc. is a biopharmaceutical company, and its common stock trades on the Nasdaq Capital Market under the ticker symbol SCYX. The company’s capital structure includes common shares that are also used in equity compensation plans through stock options, restricted stock units and warrants, making share count and pricing important to both investors and employees.
Average Trading Volume: 554,779
Technical Sentiment Signal: Strong Sell
Current Market Cap: $53.05M
Learn more about SCYX stock on TipRanks’ Stock Analysis page.